Immix Biopharma (IMMX) Expected to Announce Earnings on Tuesday

Immix Biopharma (NASDAQ:IMMX) will likely be releasing its Q3 2025 results before the market opens on Tuesday, November 11th. Analysts expect Immix Biopharma to post earnings of ($0.19) per share for the quarter. Interested persons may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Monday, November 10, 2025 at 6:00 PM ET.

Immix Biopharma (NASDAQ:IMMX) last announced its quarterly earnings data on Friday, August 8th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.01). On average, analysts expect Immix Biopharma to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Immix Biopharma Stock Performance

Shares of NASDAQ:IMMX traded down $0.18 during trading on Tuesday, hitting $3.47. 161,591 shares of the stock were exchanged, compared to its average volume of 238,276. Immix Biopharma has a 1-year low of $1.34 and a 1-year high of $4.05. The company has a market capitalization of $114.48 million, a price-to-earnings ratio of -4.49 and a beta of 0.33. The company’s fifty day simple moving average is $2.52 and its 200-day simple moving average is $2.39.

Analyst Ratings Changes

Several brokerages have recently weighed in on IMMX. Wall Street Zen lowered Immix Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, August 30th. HC Wainwright lifted their price objective on Immix Biopharma from $7.00 to $8.00 and gave the stock a “buy” rating in a report on Friday, September 12th. Zacks Research lowered shares of Immix Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 25th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Immix Biopharma in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Immix Biopharma has a consensus rating of “Hold” and an average target price of $8.00.

About Immix Biopharma

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.